BD111 not checked
Shanghai BDgene Co., Ltd. · HSV-1-erasing lentiviral particles
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “BD111: intrastromally injection, single-dosing 10E6 TU/eye, specified injection volume is 0.15mL.”In the company’s words, NCT06474442 on ClinicalTrials.gov
- Tested for
- Herpes Simplex Virus Type I Stromal Keratitis (2 trials)
- Main trialPhase 2
- “This study aims to compare the clinical efficacy and safety of BD111 injection in combination with standard therapy vs. standard therapy in herpes simplex virus type I stromal keratitis (HSK), providing preliminary confirmation of the clinical effectiveness of BD111 in combination with standard therapy.”In the company’s words, NCT06474442 on ClinicalTrials.gov
- Other names
- HSV-1-erasing lentiviral particles · HELP
Coming up1
- DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Dec 2026 | A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis | |
| Phase 1Active, not recruiting | Oct 2025 | A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026